Slide 3
Image is not available
A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
Slide 1
Image is not available
Committed to building a pharmaceutical
ecosystem focused on delivering solutions in
an open and collaborative setting for
the benefit of all stakeholders
To fulfill unmet clinical needs
Slide 2
Image is not available
Providing competitive
products and services
To enable the more effective diagnosis
and treatment, whilst enhancing clinical
practice to the ultimate benefit of the patient
previous arrow
next arrow

Innovation

Bio-technology incubation platform

Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products. 

go

INNOVATION

Business

Commercialization platform

Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.

go

BUSINESS

Cardio-cerebrovascular
and gastroenterology

Skin Health

Ophthalmology

Southeast Asia Business

News

2025-07-15

A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today

On the morning of 15 July 2025, China Medical System Holdings Limited (“CMS” or the “Group”) rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8).     Nearly one hundred representatives from global professional institutions, shareholders, business partners and employees gathered to witness this strategic moment. Following its successful IPO on the Hong Kong Stock Exchange Main Board in September 2010 , CMS advances with formidable momentum onto the international capital platform, which will attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia to optimize the shareholder structure. This listing also marks a significant milestone for the Group to deepen roots in emerging markets and advance industrial internationalization strategy.   At the listing ceremony, Chairman, Chief Executive Officer and President of CMS, Mr. Lam Kong stated: “The secondary listing in Singapore represents a crucial step in implementing CMS’s Asia-Pacific strategy, demonstrating our commitment to extending China’s market advantages across the entire APAC region while strengthening our presence in Southeast […]

go
战略合作&联系我们

Partnering

We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.

go

Contact Us

If you are interested in joining us, or curious about our business and products, please feel free to contact us.

go